Salah-Eddin Al-Batran, MD | Authors


Dr. Al-Batran on FLOT Benefit in Gastric Cancer

October 08, 2015

Salah-Eddin Al-Batran, MD, Medical Oncologist and Director, The Institute of Clinical Cancer Research and Krankenhaus Nordwest-University Cancer Center, Frankfurt, Germany discusses neoadjuvant 5-FU, oxaliplatin and docetaxel (FLOT) versus epirubicin, cisplatin and 5-FU in patients with locally advanced, resectable gastric/esophagogastric junction cancer.